Harvard Apparatus Regenerative Technology, Inc.
Close on Oct 19, 2026
- Market cap
- $38.92M
- P/E (TTM)
- –
- Dividend yield
- –
About Harvard Apparatus Regenerative Technology
Surgical & Medical Instruments & Apparatus, SIC 3841
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for disorders of the gastrointestinal system and other organs. The company operates two segments: Regenerative Biotech and Consumer Health Products. Its regenerative platform uses patient-derived stem cells seeded on temporary synthetic scaffolds to restore organs damaged by cancer, trauma, or congenital defects, with lead product candidates targeting esophageal reconstruction, colon repair, and pediatric esophageal atresia. Through its Hong Kong subsidiary, the company also markets consumer health items and dietary supplements directly to consumers via eCommerce.
The company is headquartered in Holliston, Massachusetts, where it manufactures bioreactors and scaffolds in clean-room facilities. Cell seeding operations take place at an FDA-approved facility at the University of Texas Medical Branch. The business conducts clinical trials across three activated medical centers in the United States and collaborates on research initiatives with institutions in Massachusetts, Connecticut, and Beijing, China. Its consumer health operations primarily target customers in Asia.
Summary of the business section of Harvard Apparatus Regenerative Technology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Harvard Apparatus Regenerative Technology, Inc.
- Headquarters
- Holliston, MA
- Address
- 84 October Hill Road, Suite 11 01746
- Phone
- (774) 233-7300
- Employees
- 8, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Boston, MA
Stock & identifiers
- Ticker
- HRGN
- Exchange
- OTC
- Shares outstanding
- 18M, Aug 10, 2026
- Public float
- $15.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Apr 3, 2018; 1-for-20 reverse, Dec 22, 2017
- SEC CIK
- 1563665
- EIN
- 45-5210462
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Junli He | CEO, Director | 1,332,930 |
| David Green | Director | 175,329 |
| Ronald J. Packard | Director | – |
| James E. Shmerling | Director | 23,756 |
| Jing Chen | Director | 210,000 |
| Ting Li | Director | – |
| Herman Sanchez | Director | – |
| Mao Zhang | Director | 2,113,784 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Junli (Jerry) He | $439.97K | $365.05K | $208.70K | $33 | – |
| FY2024 Mr. Junli (Jerry) He | $1.28M | $894.53K | $246.34K | $54 | – |
| FY2023 Mr. Junli (Jerry) He | $5.79M | $5.79M | $233.39K | $91 | – |
| FY2022 | $37.15K | -$10 | $227.53K | $274 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, our consolidated business employed 8 individuals.”
Corporate history
Events identified from SEC filings